Literature DB >> 3125920

Guidelines on postmarketing surveillance. Joint committee of ABPI, BMA, CSM, and RCGP.

.   

Abstract

Mesh：

Year:  1988        PMID： 3125920      PMCID： PMC2545029     

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  7 in total

1.  Physician rewards for postmarketing surveillance (seeding studies) in the US.

Authors:  J La Puma
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

2.  25 years of the Committee on Safety of Medicines. An international perspective of the benefits.

Authors:  J L Bem; S M Wood; L West; M D Rawlins; A M Breckenridge
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

3.  The code for promoting drugs.

Authors:  F O Wells
Journal:  BMJ       Date:  1988-09-10

Review 4.  Marketing aspects of company-sponsored postmarketing surveillance studies.

Authors:  M D Stephens
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

5.  Terminology in prescription-event monitoring.

Authors:  K Kubota; W H Inman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Post-marketing studies: the work of the Drug Safety Research Unit.

Authors:  F J Mackay
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

7.  Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines.

Authors:  J G Ayres; C D Frost; W F Holmes; D R Williams; S M Ward
Journal:  BMJ       Date:  1998-10-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.